RxDoctor Payments Data

Theresa Goebel, DO

Family Medicine · Hobe Sound, FLNPI 1366638835

Payments from drug & device makers

$1,320in general payments, 2019–2025

Across 50 payments — averaging $26.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$170
  • AstraZeneca$159
  • Novo Nordisk$131
  • Esperion Therapeutics, Inc.$125
  • Astellas Pharma US Inc$110
  • Edwards Lifesciences$107
  • plus $519 from 15 others

What the payments were for

  • Food & beverage$1,22593%
  • Education$957%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,320 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$388,261
Medicare patients
459
Services billed
5,551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide56$69,397
OzempicSemaglutide32$38,649
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$26,817
EliquisApixaban27$26,407
XareltoRivaroxaban17$15,292
JardianceEmpagliflozin15$13,769
Breo ElliptaFluticasone/Vilanterol25$9,884
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,917
Liothyronine Sodium109$3,946
Levothyroxine Sodium323$3,735
SynthroidLevothyroxine Sodium45$3,518
Omeprazole193$2,798
Potassium Chloride59$1,919
Duloxetine Hcl70$1,501
Eszopiclone19$1,489

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$106$69,39756 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$30$42,61874 claims
Novo NordiskOzempic$131$38,64932 claims
PfizerEliquis$65$26,40727 claims
AbbVieSynthroid$170$3,51845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Hobe Sound

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →